JP6518690B2 - （５，６−ジヒドロ）ピリミド［４，５−ｅ］インドリジン - Google Patents

（５，６−ジヒドロ）ピリミド［４，５−ｅ］インドリジン Download PDF

Info

Publication number
JP6518690B2
JP6518690B2 JP2016560952A JP2016560952A JP6518690B2 JP 6518690 B2 JP6518690 B2 JP 6518690B2 JP 2016560952 A JP2016560952 A JP 2016560952A JP 2016560952 A JP2016560952 A JP 2016560952A JP 6518690 B2 JP6518690 B2 JP 6518690B2
Authority
JP
Japan
Prior art keywords
carboxamide
anilino
dihydropyrimido
indolizine
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016560952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510595A (ja
JP2017510595A5 (https=
Inventor
マン，アドリアヌス ペトルス アントニウス デ
マン，アドリアヌス ペトルス アントニウス デ
クリスティアン ブイスマン，ロジエ
クリスティアン ブイスマン，ロジエ
ゲラルド ステーレンバーグ，ヤン
ゲラルド ステーレンバーグ，ヤン
コルネリス マリヌス ウイッデハーグ，ヨースト
コルネリス マリヌス ウイッデハーグ，ヨースト
ヴィット，ヨエリ ヨハネス ペトルス デ
ヴィット，ヨエリ ヨハネス ペトルス デ
ジェニー ルドルフ ザマン，グイド
ジェニー ルドルフ ザマン，グイド
Original Assignee
ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ．
ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ．, ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ． filed Critical ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ．
Publication of JP2017510595A publication Critical patent/JP2017510595A/ja
Publication of JP2017510595A5 publication Critical patent/JP2017510595A5/ja
Application granted granted Critical
Publication of JP6518690B2 publication Critical patent/JP6518690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016560952A 2014-04-07 2015-03-30 （５，６−ジヒドロ）ピリミド［４，５−ｅ］インドリジン Active JP6518690B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734.8 2014-04-07
EP14163734 2014-04-07
EP15153207 2015-01-30
EP15153207.4 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (3)

Publication Number Publication Date
JP2017510595A JP2017510595A (ja) 2017-04-13
JP2017510595A5 JP2017510595A5 (https=) 2018-05-17
JP6518690B2 true JP6518690B2 (ja) 2019-05-22

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560952A Active JP6518690B2 (ja) 2014-04-07 2015-03-30 （５，６−ジヒドロ）ピリミド［４，５−ｅ］インドリジン

Country Status (16)

Country Link
US (3) US9856258B2 (https=)
EP (1) EP3129374B1 (https=)
JP (1) JP6518690B2 (https=)
KR (1) KR102432420B1 (https=)
CN (1) CN106132963B (https=)
AU (1) AU2015243694B2 (https=)
BR (1) BR112016022342B1 (https=)
CA (1) CA2944610C (https=)
DK (1) DK3129374T3 (https=)
ES (1) ES2716165T3 (https=)
HU (1) HUE043108T2 (https=)
MX (1) MX368767B (https=)
PL (1) PL3129374T3 (https=)
PT (1) PT3129374T (https=)
RU (1) RU2692479C2 (https=)
WO (1) WO2015155042A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856258B2 (en) * 2014-04-07 2018-01-02 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-E]indolizines
FI3283642T3 (fi) 2015-04-17 2024-01-11 Crossfire Oncology Holding B V Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan
DK3416964T3 (da) * 2016-02-19 2021-02-22 Phoenix Molecular Designs 6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-A]pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase- (RSK-) hæmmere til behandling af cancer
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
KR20240026521A (ko) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
AU2022408915A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Methods of treating neoplastic diseases
KR20240107189A (ko) * 2021-12-15 2024-07-08 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물
MX2024007452A (es) * 2021-12-15 2024-07-09 Sillajen Inc Composiciones farmaceuticas que comprenden beta-ciclodextrinas modificadas.
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160915A0 (en) * 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
PT1636236E (pt) 2003-05-22 2013-12-16 Nerviano Medical Sciences Srl Derivados de pirazol-quinazolina, processo para sua preparação e sua utilização como inibidores de cinase
EP2118102B1 (en) 2006-11-28 2013-06-12 Nerviano Medical Sciences S.r.l. Tricyclic indoles and (4,5-dihydro) indoles
MX2010013843A (es) 2008-06-26 2011-01-21 Nerviano Medical Sciences Srl Pirazolo-quinazolinas.
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
EP2424868B1 (en) 2009-04-29 2018-01-10 Nerviano Medical Sciences S.r.l. Cdk inhibitor salts
JP5851990B2 (ja) 2009-07-29 2016-02-03 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｐｌｋ阻害剤の塩
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
CN103415518A (zh) * 2010-12-17 2013-11-27 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪
ES2602791T3 (es) * 2011-01-26 2017-02-22 Nerviano Medical Sciences S.R.L. Derivados de pirrolo tricíclicos, proceso para su preparación y su uso como inhibidores de cinasa
JP6523267B2 (ja) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用
US9856258B2 (en) * 2014-04-07 2018-01-02 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-E]indolizines

Also Published As

Publication number Publication date
US9856258B2 (en) 2018-01-02
EP3129374B1 (en) 2018-12-19
JP2017510595A (ja) 2017-04-13
RU2016141405A (ru) 2018-05-07
BR112016022342B1 (pt) 2022-10-04
CN106132963B (zh) 2019-08-06
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
RU2692479C2 (ru) 2019-06-25
EP3129374A1 (en) 2017-02-15
BR112016022342A8 (pt) 2021-07-20
MX368767B (es) 2019-10-15
PL3129374T3 (pl) 2019-07-31
HUE043108T2 (hu) 2019-07-29
CA2944610C (en) 2024-01-09
KR102432420B1 (ko) 2022-08-17
PT3129374T (pt) 2019-03-25
CA2944610A1 (en) 2015-10-15
AU2015243694B2 (en) 2019-01-17
CN106132963A (zh) 2016-11-16
BR112016022342A2 (pt) 2017-08-15
USRE48974E1 (en) 2022-03-15
ES2716165T3 (es) 2019-06-10
MX2016012997A (es) 2016-12-07
USRE50082E1 (en) 2024-08-20
RU2016141405A3 (https=) 2018-10-02
DK3129374T3 (en) 2019-04-08
KR20170013866A (ko) 2017-02-07
AU2015243694A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
JP6518690B2 (ja) （５，６−ジヒドロ）ピリミド［４，５−ｅ］インドリジン
AU2020255100B2 (en) N-heteroaromatic amide derivatives for treatment of cancer
KR101238585B1 (ko) 단백질 키나제 억제제로서의 화합물 및 조성물
AU2016352813B2 (en) Novel pyrazolo pyrimidine derivatives
ES2904544T3 (es) Compuestos de indazol como inhibidores de la cinasa FGFR, preparación y uso de los mismos
US9567342B2 (en) Certain protein kinase inhibitors
CN114269735A (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
CA3098574A1 (en) Kras g12c inhibitors and methods of using the same
KR20130096241A (ko) Ａｌｋ 억제제로서 4-(1ｈ-인돌-3-일)-피리미딘
WO2005063709A1 (ja) アミド誘導体及び医薬
JP2025526419A (ja) グルタミニル－ペプチドシクロトランスフェラーゼ及びグルタミニル－ペプチドシクロトランスフェラーゼ様タンパク質の阻害剤としてのピペリジニルピリジニルカルボニトリル誘導体
US20170233395A1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
KR20160007348A (ko) 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
CA2967551A1 (en) Imidazopyridazine derivatives as pi3k.beta. inhibitors
IL322876A (en) A disintegrant containing an aryl substituent for CDK12/13, a method for its preparation, as well as a pharmaceutical composition and medical use thereof
CN103570731A (zh) 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用
HK1231072A1 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
HK1231072B (zh) (5，6-二氢)嘧啶并[4，5-e]吲嗪

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190422

R150 Certificate of patent or registration of utility model

Ref document number: 6518690

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250